📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. (2018)

First Author: Woodcock VK
Attributed to:  Centre for Integrated research into Musculoskeletal Ageing (CIMA) Renewal funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2017.484

PubMed Identifier: 29438361

Publication URI: http://europepmc.org/abstract/MED/29438361

Type: Journal Article/Review

Volume: 118

Parent Publication: British journal of cancer

Issue: 6

ISSN: 0007-0920